MCKEON BRIAN P purchased $101K of XRAY (indirect holdings)

MCKEON BRIAN P purchased 10,000 indirectly-held shares of DENTSPLY SIRONA Inc. (XRAY) at $10.12 ($0.10M total) on 2026-06-12.

Original reporting
SEC EDGAR · MCKEON BRIAN P
Published Jun 15, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XRAY
Neutral
low confidence
Mentioned
$XRAY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XRAYNeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase details (10,000 shares at $10.12) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the buy as mild sentiment, but there is no fundamental catalyst in the text.

03

What to watch

The transaction is indirect and the article provides no context on size versus prior holdings beyond the post-transaction share count.

Relevance 5/10Novelty 6/10Timing: Filed June 15; transaction dated June 12.

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

$XRAYNeutralLow confidence
Context

Dentsply Sirona director Brian P. McKeon filed an SEC Form 4 showing an open-market purchase of 10,000 XRAY shares at $10.12.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and small versus broader fundamentals.

Evidence & confidence

The filing is a routine Form 4 transaction with no 10b5-1 plan and no accompanying company news (no earnings, guidance, deal, or regulatory action).

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary or part of personal liquidity planning; without follow-on disclosures, signal quality is low.

Key entities

  • DENTSPLY SIRONA Inc.

    Company whose shares were purchased; insider transaction disclosed on SEC Form 4.

  • MCKEON BRIAN P

    Director who reported an open-market purchase of XRAY shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

$XRAYMedAI 8/10

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.